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Prophage P4 immunity is elicited by a short, 69-nucleotide RNA (CI RNA) coded for within the untranslated
leader region of the same operon it controls. CI RNA causes termination of transcription that starts at the
promoter PLE and prevents the expression of the distal part of the operon that codes for P4 replication
functions (a operon). In this work, we identify two sequences in the untranslated leader region of the a operon,
seqA and seqC, that are the targets of the P4 immunity factor. seqA and seqC exhibit complementarity to a
sequence internal to the CI RNA (seqB). Mutations in either seqA or seqC that alter its complementarity to seqB
abolished or reduced P4 lysogenization proficiency and delayed the shutoff of the long transcripts originating
from PLE that cover the entire operon. Both seqA and seqC single mutants were still sensitive to P4 prophage
immunity, whereas P4 seqA seqC double mutants showed a virulent phenotype. Thus, both functional sites are
necessary to establish immunity upon infection, whereas a single site appears to be sufficient to prevent lytic
gene expression when immunity is established. A mutation in seqB that restored complementarity to both seqA
and seqC mutations also restored premature termination of PLE transcripts, thus suggesting an important role
for RNA-RNA interactions between seqB and seqA or seqC in P4 immunity.
In most known temperate bacteriophages, prophage immu-
nity is determined by a repressor protein which prevents tran-
scription initiation at promoters controlling the expression of
replication functions and of other genes involved in the lytic
cycle. Satellite bacteriophage P4 deviates from this model in
two respects. (i) Prophage immunity does not prevent tran-
scription initiation of the operon encoding the replication
functions (a operon); rather, it promotes premature termina-
tion of transcription that initiates at PLE, the constitutive pro-
moter of the a operon (9, 10, 12). (ii) The immunity factor is
not a protein but a small, 69-nucleotide (nt) RNA (CI RNA)
exhibiting complementarity with the nontranslated leader re-
gion of the transcripts it regulates (10, 11a, 12).
P4 depends on all the morphogenetic genes of a helper
phage such as P2 to assemble the viral particle. Autonomous
P4 replication requires the expression of a primase-helicase
coded for by the P4 a gene (14, 35) and leads either to the lytic
cycle (when a helper phage genome is present in the host cell)
or to a multicopy plasmid state (in the absence of the helper).
As an episome, P4 may also integrate in the host chromosome
and establish the lysogenic condition (for a review, see refer-
ence 21).
Central to the choice and the maintenance of the lysogenic
versus the lytic or plasmid condition is the regulation of P4
replication genes (Fig. 1). Soon after infection of a sensitive
host, transcription of the a operon starts at the constitutive
promoter PLE. Transcription from PLE seems to be intrinsically
termination prone, and transcripts of different lengths (0.3 to
0.5, 1.3, and 4.1 kb) are produced. At a later time as well as in
the lysogenic state, production of transcripts longer than 0.3 to
0.4 kb initiating at PLE is prevented by premature transcription
termination (9, 10). This is dependent on a functional immu-
nity RNA factor (CI RNA) which is coded for by the untrans-
lated leader region of the a operon itself (cI gene) and is
generated by the processing of the primary transcript (10, 11a,
12) (Fig. 1B). A region in the CI RNA (seqB) exhibits high
complementarity with seqA, a sequence immediately down-
stream of PLE. All P4 immunity-defective recessive mutants
isolated so far carry a mutation in cI, and most of the muta-
tions fall in seqB. This suggested that the P4 immunity factor
controls termination of transcription that starts at PLE by spe-
cific RNA-RNA interactions between CI and the nascent tran-
script (10, 12).
Thus, in P4, both immunity and replication functions are
coded for by the same operon. Transcription from PLE of the
operon distal portion, which encodes the replication functions,
occurs only soon after infection, before the CI RNA immunity
factor is produced by the processing of the primary transcript.
Later on, transcription from PLE is restricted by enhancement
of premature transcription termination efficiency to the prox-
imal part of the operon which encodes the immunity factor
itself.
Expression of the a operon late in the lytic cycle and in the
plasmid condition is made possible by activation of PLL, a
positively regulated promoter located 400 nt upstream of PLE
(9). Transcription from PLL is insensitive to transcription ter-
mination controlled by P4 immunity, probably because trans-
lation of two open reading frames (orf88 and orf199) at the 59
end of the PLL mRNA protects the nascent transcript from the
action of the immunity factor (Fig. 1) (23a).
To elucidate the peculiar immunity mechanism of P4 and
understand how a small RNA may control transcription termi-
nation, it is fundamental to identify the target(s) of the RNA
immunity factor. In this work, we show that the previously
identified element seqA is indeed involved in the control of P4
immunity; moreover, we identify an additional site (seqC) in
the untranslated leader region of the a operon which is also
complementary to seqB and is involved in P4 lysogenization.
Evidence that seqA and seqC represent the target sites for the
CI RNA immunity factor is presented.
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MATERIALS AND METHODS
Bacteria, phages, and plasmids. The bacterial strains used were derivatives of
Escherichia coli C-1a (prototrophic) (26), C-2404 [galK(Am) recA] (12), C-5201
(polyauxotrophic str-1) (7), C-5202 (polyauxotrophic str-1 supD) (7), and C-5505
(polyauxotrophic str-1 pcnB::Tn10) (12) and their P2 (P2 lg, a large plaque
former) (2) and P4 lysogenic derivatives; in the text, the prophage is indicated in
parentheses following the name of the parental strain. P4 derivatives and plas-
mids carrying P4 genome fragments are listed in Table 1. The plasmid vectors
used were pKO1 (23), pTTQ18 and pTTQ19 (30), and pUC8 (33). The cloned
P4 DNA fragments are diagrammed in Fig. 1. The P4 genome coordinates are
from the updated P4 DNA sequence (GenBank accession number X51522) (15,
36).
pGM318 was constructed by cloning the P4 8496 to 8693 region in pTTQ18.
The region was obtained by PCR of P4 DNA with the oligos A and B being used
as primers (see below) and by digestion with AluI. The kpn1 mutation was
created by overlap extension and PCR amplification (see below) of P41 8594 to
9127 with the mutated primers kpn4 and npk5. The fragment, digested with
MluI(8623) and XmnI(9103), was cloned in pGM236 digested with the same
enzymes, giving pGM324. seqA405 and seqA8 were created by overlap extension
and PCR amplification of P41 8594 to 8785 with the mutated primers 6-7 and
8-9, respectively. The fragments, digested with MluI (Klenow filled) and KpnI,
were cloned in pUC18 SalI (Klenow filled)-KpnI, giving pGM322 and pGM323,
respectively. The seqC405 mutation was created by overlap extension and PCR
amplification of either P41 (to give pGM327) or the P4 cI405 (pGM326) 8303 to
8645 fragment with the mutated primers 10 and 11, whereas to produce seqC8
(pGM329), the oligos 12 and 13 were used. The fragments, digested with
BglI(8371)-MluI(8624), were cloned in pGM13 treated with the same enzymes.
The sequence of the cloned regions obtained by PCR was confirmed by sequenc-
ing.
All the site-specific mutations obtained by PCR mutagenesis were transferred
in the phage genome by in vitro recombination of suitable restriction fragments,
and the mutant phage was recovered by transfection of C-5202(P2) as described
(1). The genotype of the recombinant phage was confirmed by sequencing the
relevant region.
Oligonucleotides and RNA probes. The oligonucleotides used for PCR are the
following (the coordinates are those of the P4 sequence in the oligo 59 to 39
direction, and the base changes from the P4 sequence [P4 base-position-base
change] are reported): oligo 6, 8679 to 8645, G8663A; oligo 7, 8647 to 8680,
C8663T; oligo 8, 8679 to 8645, A8662G; oligo 9, 8647 to 8680, T8662C; oligo 10,
8393 to 8426, C8411T; oligo 11, 8426 to 8394, G8411A; oligo 12, 8393 to 8426,
T8410C; oligo 13, 8426 to 8394, A8410G; oligo A, 8361 to 8380; oligo B, 8693 to
8680; oligo kpn4, 8793 to 8759, G8772C; oligo npk5, 8749 to 8783, C8772G; oligo
vir1, 9088 to 9110; and oligo vir1, 9088 to 9110, G9099A. The g-32P-labelled
RNA probes PLE-t2 and SeqB were prepared as described (10) and cover P4
8418 to 8774 and 8418 to 8470, respectively.
P4 mutagenesis and screening of P4 virulent mutants by lysis spot hybridiza-
tion. UV light mutagenesis of P4 was performed as described by Ghisotti et al.
(12). To identify virulent mutants, the P4 clear plaques obtained were purified
and replica plated on C-5201(P2)(P4). Spontaneous virulent mutants were ob-
tained by plating about 108 P4 PFUs on the P2-P4 double lysogen.
To distinguish between vir1-like (promoter up mutations in PLL) and virulent
mutants of a different kind, spontaneous and UV-induced virulent phages were
hybridized to 32P-labelled vir1 or vir1 oligonucleotides corresponding to either
the P4 vir1 or the P41 210 region of the PLL promoter, respectively. P4 virulent
plaques were resuspended in microtiter wells and replica plated on C-5201(P2 lg)
indicator. The P4 DNA of the lysis spots was immobilized on two nitrocellulose
filters as described previously for phage lambda plaques (25), and the filters were
hybridized to vir1 and vir1 oligonucleotides that were 59 end labelled with T4
polynucleotide kinase in the presence of [g-32P]ATP, as described previously
(25). Hybridization was performed in 63 SSC (13 SSC is 0.15 M NaCl plus 0.015
M sodium citrate) (pH 7) containing 0.05% sodium pyrophosphate and 0.5%
sodium dodecyl sulfate at 488C for 18 h. The filters were washed three times at
room temperature and once at 588C with 63 SSC–0.05% sodium pyrophosphate.
These conditions allowed specific hybridization only to the fully complementary
DNA, whereas a single mismatch was sufficient to prevent hybridization.
Base-directed mutagenesis by PCR overlap extension. Specific base substitu-
tion mutants were generated by the procedure described by Ho et al. (17). In
summary, two complementary synthetic oligonucleotides carrying the desired
base substitution and two external primers were used in two independent PCRs
to generate two DNA fragments having one overlapping end sequence. These
two fragments were combined in a subsequent PCR in which the annealed
overlapping ends of each strand served as primers for the 39 extension on the
complementary strand, thus generating a fusion DNAmolecule further amplified
by the external primers. The fragment so obtained was cut by restriction enzymes
and cloned in a suitable plasmid. Both strands of the region containing the
mutation to be used for the construction of other recombinant plasmids and
phage were fully sequenced. In order to limit the region to be sequenced and to
facilitate the transfer of the desired mutation in P4, we created the kpn1 muta-
tion in pGM324 by PCR mutagenesis and transferred it in P4. P4 kpn1, which
carries a unique KpnI restriction site, was then used for all subsequent P4 mutant
strain constructions.
Complementation test of P4 clear plaque mutants. Ten microliters (each) of
two clear plaque mutant stocks of about 108 PFU ml21 were cross streaked on
C-5201(P2 lg) indicator. Turbid indicator outgrowth at the crossing of the two
clear streaks indicated complementation for immunity.
P4 one-step growth and screening for P4 lysogens in a P2 lysogenic host. The
bacterial strains were grown at 378C in LD broth (1% tryptone, 0.5% yeast
extract, 0.5% NaCl) supplemented with 5 mM CaCl2 (to allow P4 adsorption)
and 100 mg of ampicillin ml21 (if the strain carried an Ampr plasmid) to 40 Klett
colorimeter units, equivalent to 108 cells ml21. When induction of the Ptac
promoter of the resident plasmid was required, IPTG (isopropyl-b-D-thiogalac-
topyranoside) was added to a final concentration of 40 mg ml21 and the cultures
were further incubated for 1 h at 378C and diluted to 40 Klett units before the
infection. The cells were then infected with P4 with the intent of achieving a
multiplicity of infection of 10 and incubated at 378C. After 15 min, phage
adsorption was measured and P4 antiserum (K value, 1) was added to inactivate
the unadsorbed phage; after 20 min, the cells surviving the infection and the cells
yielding phage progeny (yielders) were assayed. A culture sample was diluted
104-fold in LD (with ampicillin if the strain carried an Ampr plasmid) and
incubated for 40 min at 378C with aeration, and the phage titer produced was
assayed. The clones surviving the infection were analyzed for lysogeny by testing
their ability to release the prophage and their sensitivity to P4 cI405 and P4 vir1.
Infection with P4 and screening for P4 lysogens and plasmid carriers in the
absence of P2 (cox test). Cell growth, infection with P4, and measurement of the
survivors were performed as in the one-step-growth experiment. The screening
of the lysogens and P4 plasmid carriers among the survivors was performed as
described previously (8). The test is based on the fact that the helper P2 cox gene
is necessary to induce the P2 lytic cycle upon P2 infection of a P4 lysogen but is
not required when P4 is in the plasmid condition (8, 29). Thus, the P4 lysogens
were identified as the clones that released P4 following infection with P2 cox1
but not with P2 cox4, whereas P4 plasmid carriers among the survivors released
P4 following infection with both P2 cox1 and P2 cox4.
Northern (RNA) blot hybridization. RNA was extracted from E. coli and from
P4-infected cells as described previously (9) and fractionated by either 1.5%
FIG. 1. P4 map. (A) Genetic and physical map of phage P4 and transcripts of
P4 essential region. The transcripts produced during the early, late-plasmid, and
lysogenic regulatory states are indicated by arrows; the transcripts of the lyso-
genic state are detailed in panel B. The sizes of the transcripts are indicated at
the left in kilobases. (B) Map of the P4 immunity region and of cloned P4 DNA
fragments. The fragments cloned in the expression vectors pTTQ18 and pTTQ19
are identified by the addition of the promoter (ptac). The seqA and seqB coor-
dinates are 8676 to 8640 and 8479 to 8432, respectively; for those of seqC, see the
text. The coordinates of the P4 DNA fragments are reported in Table 1. Data are
from references 9, 10, 12, 15, 32, and this work. ORF, open reading frame.
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formamide-formaldehyde agarose or 10% polyacrylamide-urea denaturing gel
electrophoresis, following the procedure detailed by Sambrook et al. (25). RNA
was transferred from the agarose gels onto Hybond-N filter membranes (Amer-
sham) by vacuum blotting and from the acrylamide gels onto the same type of
membranes by electroblotting. Hybridization to the specific riboprobes was per-
formed as described previously (10).
RESULTS
Transcription of cloned seqA interferes with the establish-
ment of P4 immunity. In a previous study, it was shown that a
cloned 357-bp fragment of P4 DNA encompassing PLE, seqA,
TABLE 1. Bacteriophage P4 derivatives and plasmids
Bacteriophage or
plasmid (vector)
Relevant properties and origin (bacteriophages)
or cloned P4 region (plasmids) Mutation
Source or
reference
Bacteriophages
P4 Wild type 28
P4 ash3 C8477A mutation in cI 20
P4 ash8 T8447C mutation in cI 20
P4 ash9 T8448A mutation in cI 20
P4 ash29 G8433A mutation in cI 20
P4 ash29 seqC30 Spontaneous virulent mutant from P4 ash29; C8382A mutation in seqC This work
P4 ash29 seqC31 Spontaneous virulent mutant from P4 ash29; C8382A mutation in seqC This work
P4 cI9 C8446T mutation in cI (same as cI405) 4, this work
P4 cI10 T8473C and C8474G double mutation in cI 4, this work
P4 cI405 C8446T mutation in cI 4, 20
P4 cIIam3 Makes clear plaques, complements cI mutants 4
P4 kpn1 G8772C mutation, creates a unique KpnI restriction site; by substitution
of P4 MluI(8623)-ApaLI(10651) fragment of pGM324 in P41
This work
P4 kpn1 cI405 By substitution of P4 MluI(8623)-ApaLI(10651) fragment of pGM324 in
P4 cI405
This work
P4 kpn1 seqA8 A8662G mutation in seqA; by substitution of P4 MluI(8623)-KpnI(8772)
fragment of pGM323 in P4 kpn1
This work
P4 kpn1 seqA8 seqC8 By substitution of P4 MluI(8623)-KpnI(8772) fragment of pGM323 in P4
kpn1 seqC8
This work
P4 kpn1 seqA405 G8663A mutation in seqA; by substitution of P4 MluI(8623)-KpnI(8772)
fragment of pGM322 in P4 kpn1
This work
P4 kpn1 seqA405 cI405
seqC32
Spontaneous virulent mutants from P4 kpn1 seqA405 cI405; seqC32 is
G8419T
This work
P4 kpn1 seqA405 cI405
seqC33
Spontaneous virulent mutant from P4 kpn1 seqA405 cI405; seqC33 is
T8407C
This work
P4 kpn1 seqA405 cI405
seqC405
By substitution of P4 MluI(8623)-KpnI(8772) fragment of pGM326 in P4
kpn1 seqA405
This work
P4 kpn1 seqA405
seqC405
By substitution of P4 Tth111I(7772)-MluI(8623) fragment of pGM327 in
P4 kpn1 seqA405
This work
P4 kpn1 seqC8 A8410G mutation in seqC; by substitution of P4 Tth111I(7772)-
MluI(8623) fragment of pGM329 in P4 kpn1
This work
P4 kpn1 seqC405 G8411A mutation in seqC; by substitution of P4 Tth111I(7772)-
MluI(8623) fragment of pGM327 in P4 kpn1
This work
P4 seqC30 By ligation of fragments TaqI(8418)-MluI(8623) and MluI(8623)-cos-
Tth111I(7772) of P41 with fragment Tth111I(7772)-TaqI(8418) of P4
ash29 seqC30
This work
P4 vir1 C9099T mutation in PLL 22
Plasmids (vectors)
pGM13 (pUC8) DraI(7656)-DraI(9191) This work
pGM85 (pKO1) TaqI(8418)-RsaI(8774) cI405 (C8446T) This work
pGM152 (pKO1) TaqI(8418)-RsaI(8774) 12
pGM156 (pKO1) AvaI(8656)-RsaI(8774) 12
pGM230 (pKO1) HaeIII(8471)-RsaI(8774) 12
pGM236 (pUC8) HincII(6447)-BamHI(10657) This work
pGM304 (pKO1) AluI(8496)-HpaII(8719) This work
pGM305 (pKO1) AluI(8496)-HpaII(8674) This work
pGM306 (pKO1) MluI(8623)-RsaI(8774) 12
pGM307 (pKO1) HaeIII(8471)-RsaI(8774) Deletion MluI(8623)-
AvaI(8656)
This work
pGM317 (pTTQ19) AluI(8496)-RsaI(8774) This work
pGM318 (pTTQ18) AluI(8496)-8693 This work
pGM322 (pUC18) MluI(8623)-KpnI(8772) seqA405 (G8663A) This work
pGM323 (pUC18) MluI(8623)-KpnI(8772) seqA8 (A8662G) This work
pGM324 (pUC18) HincII(6447)-BamHI(10657) kpn1 (G8772C) This work
pGM326 (pUC8) DraI(7656)-DraI(9191) cI405 seqC405 This work
pGM327 (pUC8) DraI(7656)-DraI(9191) seqC405 (G8411A) This work
pGM329 (pUC8) DraI(7656)-DraI(9191) seqC8 (A8410G) This work
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and cI (pGM152 on Fig. 1B) conferred P4 immunity to the
bacterial host, thus preventing P4 plaque formation, whereas
shorter fragments (pGM230 and pGM306) containing PLE and
seqA caused P4 to make clear plaques. An even shorter frag-
ment (pGM156) missing the distal part of seqA did not affect
the P4 turbid plaque morphology. This suggested that the
presence of seqA without cI on the plasmid vector interfered
with P4 lysogenization by titrating out the immunity factor
produced by the superinfecting phage and that interactions
between the complementary sequences seqA and seqBmight be
involved in P4 immunity control (10, 12).
To define whether the cloned fragments discussed above
would actually interfere with P4 immunity establishment
and/or maintenance, we tested their effect on the choice of the
lysogenic versus the lytic or plasmid condition. Cells harboring
the appropriate plasmid were infected with P4; 20 min later, we
assayed the cells surviving the infection and, in the P2 lysogen,
the cells producing P4 phage (yielders). The survivors were
then tested for P4 lysogeny and, in the P2 nonlysogenic host,
for the presence of P4 in the plasmid condition, as described in
Materials and Methods. The lysogenization index was calcu-
lated as the ratio of the lysogenic cells to either the yielders or
the P4 plasmid carriers. To avoid recombination between the
infecting phage and the resident plasmid, the experiments were
performed in recA hosts.
In the P2 lysogenic host (Table 2), the cloned P4 fragments
containing both PLE and seqA (pGM230 and pGM306) caused
a reduction of the cell fraction surviving P4 infection and an
increase in yielder frequency by comparison with the controls
(the vector pKO1 and pGM156 that carries PLE and only the 59
half of seqA). In the absence of P2 (Table 2), pGM230 and
pGM306 greatly increased the frequency of clones carrying P4
as a plasmid. Nevertheless, P4 lysogens could be recovered
both in the presence and in the absence of P2. Thus, it ap-
peared that the P4 cloned fragments would favor the lytic cycle
and the establishment of the plasmid state and greatly reduce
the lysogenization index. We shall call this effect anti-immu-
nity.
To define more precisely the elements required for anti-
immunity, we made deletions of either seqA (pGM307) or PLE
(pGM304 and pGM305) (the former is missing the 235 region
of PLE, whereas in the latter, the deletion completely removes
the promoter and the first 4 nt of seqA [Fig. 1]). Deletion of
either seqA or PLE was sufficient to abolish the anti-immunity
effect (see data for pGM307, pGM304 and pGM305 [Table 2]).
Moreover, a plasmid carrying the seqA region under the con-
trol of the inducible promoter Ptac (pGM318) exhibited the
anti-immunity effect only when transcription was induced by
IPTG (Table 2), suggesting that transcription of the seqA re-
gion was necessary for the anti-immunity effect to occur. IPTG
did not affect the outcome of P4 infection in the control plas-
mid pGM317 in which seqA can be transcribed both from Ptac
and the constitutive promoter PLE.
The P4 lysogens of the strains carrying the anti-immunity
plasmids could be stably maintained. In the presence of P2, the
titer of P4 spontaneously released by the strains carrying the
anti-immunity fragments was 10- to 100-fold higher than that
of control strains; in the absence of P2, segregation of P4
plasmid carriers was detectable in the strain carrying pGM306
(up to 50% of P4 plasmid-carrying clones in overnight cul-
tures) but was below the detection limit (,1023) with
pGM230.
These data indicate that transcription of the P4 seqA region
from a plasmid vector interferes with the establishment of P4
immunity but that it is compatible with the maintenance of the
lysogenic state.
Transcription of the P4 a operon from PLE in the presence
of anti-immunity plasmids. We then tested whether the anti-
immunity plasmids would interfere with the normal P4 tran-
scription pattern from PLE. Cells carrying either the anti-im-
munity plasmid pGM230 or the control vector pKO1 were
infected with P4; the RNA was extracted at different times
after infection and analyzed by Northern blot hybridization
with a PLE proximal probe. As can be seen from Fig. 2A, the
early 4.1-kb mRNA, which covers the entire a operon, was no
longer detectable 20 min after infection of control cells, as
previously observed (9, 10). In contrast, in cells carrying the
anti-immunity plasmid pGM230, the amount of the 4.1-kb
mRNA greatly increased up to 20 min after P4 infection (ex-
pression of the 1.3-kb mRNA produced by P4 could not be
analyzed in this experiment because of the presence of tran-
scripts of a similar size produced by pGM230). This RNA
TABLE 2. Interference with P4 lysogenization by cloned fragments of the P4 immunity region
Plasmid
carried
Host infected: C-2404(P2) Host infected: C-2404
Survivors
(%)
Yielders
(%)a
Lysogens
(%)b
Lysogenization
indexc
Survivors
(%)
P4 plasmid carriers
(%)b
Lysogens
(%)b
Lysogenization
indexc
pKO1 38.0 81 98 4.6 3 1021 140 0.33 88 267
pGM230 1.1 104 89 9.4 3 1023 83 11.0 86 7.8
pGM306 0.4 125 78 2.4 3 1023 63 47.0 49d 1.0
pGM156 29.0 88 100 3.3 3 1021 86 ,0.6 93 .155
pGM307 27.0 89 NDe 122 0.3 82 273
pGM304 24.0 64 ND 64 1.9 88 46.3
pGM305 31.0 96 ND 114 0.3 81 270
pTTQ 25.5 62 66 2.7 3 1021
pTTQf 30.3 47 82 5.2 3 1021
pGM317 1.2 149 80 6.4 3 1023
pGM317f 0.8 147 80 4.3 3 1023
pGM318 36.7 50 89 6.7 3 1021
pGM318f 0.3 90 61 1.9 3 1023
a Relative to the infected cells; yielders were assayed 20 min after infection, which may justify the greater than 100% figures.
b Among survivors.
c Ratio of lysogens to either plasmid carriers (in C-2404) or yielders (in the P2 lysogen) normalized to the infected cells.
d Lysogens were unstable and segregated P4 plasmid carriers.
e ND, not determined.
f In these cases, 40 mg of IPTG ml21 was added both to the culture 60 min before P4 infection and to the plates for the assay of survivors.
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species, however, almost disappeared 60 min after infection
and could not be detected in the P4 lysogen. We also used
Northern blot hybridization with a CI RNA specific probe to
examine whether the anti-immunity plasmid would interfere
with the production of the P4 immunity factor. As can be seen
from Fig. 2B, no substantial difference between the anti-im-
mune host and the control was apparent with respect to the
time and the amount of CI RNA production.
It thus appears that the presence of the anti-immunity plas-
mid greatly delays the shutoff of long mRNAs originating at
PLE upon P4 infection. However, the anti-immunity plasmid
did not interfere significantly either with the synthesis of the CI
RNA or with the P4 transcription pattern of a lysogenic cell.
Effect of seqA mutations on anti-immunity. The simplest
explanation for the anti-immune effect is that the RNA pro-
duced by the cloned fragment titrates out the CI RNA pro-
duced by the infecting phage; this would delay the turnoff of
long-mRNA production, thus opposing the establishment of
P4 immunity.
Titration of the P4 immunity factor could depend on RNA-
RNA interactions between the complementary sequences seqA
and seqB. To test this idea, we introduced two mutations in the
anti-immunity fragment of pGM306 by in vitro site-specific
mutagenesis (17) and tested their effect on anti-immunity.
These mutations altered the complementarity of seqA with
seqB (seqA8 [A8662G] and seqA405 [G8663A]) (Fig. 3). For
reasons that will become apparent, the base substitutions
seqA8 and seqA405 were such as to restore complementarity
with the mutated seqB of the known P4 immunity-defective
mutants ash8 and cI405, respectively. The seqA405 mutation in
pGM322 abolished anti-immunity, as evidenced by the turbid
plaques made by P4 on a strain carrying this plasmid, thus
supporting the idea of a seqA-seqB interaction via complemen-
tary base pairing. The seqA8 mutant plasmid (pGM323), how-
ever, still caused P4 to form clear plaques and thus exhibited
the anti-immunity effect. This might be due to the fact that the
A-to-G transition in seqA8 may still allow pairing with the
corresponding U in seqB.
seqA is necessary for P4 immunity. The data given above
support the hypothesis that seqA is an RNA target for the P4
CI immunity factor. However, they do not define the role that
seqA may play in the bacteriophage immunity mechanism, in
which seqA might function either as an anti-immunity deter-
minant or as an element necessary for immunity. To investigate
this further, we transferred the seqA mutations into P4 by in
vitro recombination. Both P4 seqA8 and P4 seqA405 made
clear plaques and were unable to lysogenize in both P2 lyso-
genic and nonlysogenic strains (Table 3); however, contrary to
the expectation for mutants in the target of the immunity
factor, they did not form plaques on P4 lysogenic hosts and
were therefore sensitive to P4 immunity (Table 4 and data not
shown). This suggests either that seqA is not a target for the
immunity factor or that an additional target(s) is involved in
the P4 immunity mechanism and that multiple mutations are
required for virulence.
In a cross-streak complementation test with P4 clear plaque
mutants (see Materials and Methods), P4 seqA8 and seqA405
mutants did not complement one another or cI mutants for
immunity (the streaks remained clear at the crossing with P4
cI405, P4 ash3, and P4 ash29), whereas complementation was
observed (turbid area at the crossing) with P4 cIIam3, a clear
plaque mutant that belongs to the cII complementation group
(4, 13). Thus, both P4 seqA8 and seqA405 appear to be reces-
sive immunity-sensitive mutants.
Isolation of P4 mutants insensitive to immunity: identifica-
tion of the seqC locus. In order to identify the target(s) for the
P4 immunity factor, we sought mutants that were insensitive to
immunity. The only virulent mutant characterized so far, P4
vir1, carries a promoter up mutation in the 210 region of PLL
and activates transcription from this promoter, which is insen-
sitive to transcription termination controlled by P4 immunity
(9, 20, 22).
To identify virulent mutants of a different kind, we screened
P4 virulent mutants by plaque hybridization with 32P-labelled
oligonucleotides corresponding either to the wild type or to the
vir1 210 region of PLL (see Materials and Methods). In a first
survey of spontaneous and UV-induced P4 virulent mutants
derived either from a wild-type phage or from immunity-de-
fective cI mutants (ash8, ash9, cI9, cI10, and cI405) (Table 1),
14 out of 14 independent mutants analyzed carried a mutation
in PLL. It thus appears that when P4 virulent mutants are
selected for, PLL promoter up mutations are most likely ob-
tained.
To circumvent this problem, we selected for virulent deriv-
atives of P4 ash29 and P4 seqA405 cI405 mutants. ash29
(G8433A) is a pleiotropic mutation that confers a weak immu-
nity defect on P4 and suppresses the virulence of P4 vir1 (19,
27a). This latter phenotype appears to be due to the polarity of
the amber mutation created in orf199 that leads to the prema-
ture termination of transcription starting at PLL (23a). The
suppression of virulence could therefore decrease the inci-
dence of PLL promoter up mutations. On the other hand, if
multiple mutations were required for virulence, the presence
of seqA405 could increase the frequency of virulent mutants.
From P4 ash29, we obtained and analyzed two independent
virulent derivatives that hybridized only to the oligo vir1 and
carried an additional mutation (seqC30 and seqC31, respective-
ly); both mutations turned out to be the same C8382A trans-
version. From P4 seqA405 cI405, we isolated the virulent de-
rivatives seqC32 (G8419T) and seqC33 (T8407C). These
FIG. 2. Northern blot analysis of P4 a operon transcription in the presence
of the anti-immunity plasmid pGM230. RNA was extracted from cultures of
C-2404(pKO1) (control vector plasmid) or C-2404(pGM230) (which carries the
anti-immunity region) before infection (2) and 10, 20, and 60 min following P4
infection, as indicated at the top of panel A (lanes 1 to 8); lanes 9 and 10 are
noninfected P4 lysogenic (l) strains C-2404(P4)(pGM230) and C-2404(P4), re-
spectively. (A) The RNA was fractionated by 1.5% agarose gel electrophoresis
and hybridized to the riboprobe PLE-t2 (see Materials and Methods). The ap-
parent sizes of the P41 transcripts, as previously determined (9, 10), are indi-
cated in kilobases on the left. Hybridization signals longer than 0.3 kb in the P4
lysogenic C-2404(pGM230) host are of pGM230 origin, as evidenced by the lack
of hybridization with a P4 PLE distal probe (data not shown). (B) The RNA
(lanes 1 to 9) was fractionated by 10% acrylamide–7 M urea gel electrophoresis
and hybridized to the riboprobe SeqB (see Materials and Methods). Only the
bands corresponding to CI RNA are shown.
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mutations drew our attention to a region we called seqC,
which, like seqA, presents high complementarity with seqB.
seqC is located downstream of cI and is split into two portions,
seqC9 (8402 to 8424) and seqC0 (8362 to 8384), by a 17-nt
sequence with hyphenated dyad symmetry; all of the sponta-
neous mutations in seqC listed above are changes in bases
complementary to seqB (Fig. 1 and 3).
The isolation of such mutants indicates that seqC is involved
in the control of P4 immunity. To study its role, we constructed
a P4 seqC30 single mutant by in vitro recombination; more-
over, we created two additional mutations in seqC by base-
specific mutagenesis. These mutations, seqC8 (A8410G) and
seqC405 (G8411A) (see Materials and Methods) (Fig. 3), al-
tered the complementarity with seqB; such mutations would
also restore the complementarity of seqC with seqB for ash8
and cI405 mutants, respectively. Then, by in vitro recombina-
tion, we constructed a number of P4 mutants carrying single or
multiple mutations in seqA, seqB, and seqC (Table 1) and
tested their effect on P4 lysogenization (Table 3).
In a P2 lysogenic strain, both P4 seqC30 and P4 seqC405
single mutants gave clear plaques and were defective in lyso-
genization. In the absence of the helper, both P4 lysogens and
plasmid-carrying clones could be obtained, although both types
appeared to be unstable (Table 3). However, like the seqA
mutants, the seqC single mutants could not form plaques on a
P2-P4 double lysogen (Table 4 and data not shown); thus, they
were still sensitive to P4 prophage immunity. By a cross-streak
complementation test, they appeared to belong to the cI
FIG. 3. Immunity region of bacteriophage P4 and interactions between CI RNA and seqA-seqC. (A) The complementary strand of the P4 8300 to 8800 region (15)
is shown. Under the sequence are indicated the mutations in this region that are mentioned in the text. seqA and seqC are indicated by dots. The region coding for
CI RNA is boxed; the bases in the seqB region complementary to seqA and to seqC are indicated by the upper and the lower set of dots, respectively. 3 , transcription
startpoint (11) of PLE; , stop codon of orf88; — , start codons of orf199 and kil. The ribosome-binding site for kil (SD) is underlined. (B) Predicted secondary
structure of the CI RNA and possible interactions with the 59 end of the PLE transcript (SeqA RNA) and the region containing seqC (SeqC RNA). seqB-seqA and
seqB-seqC complementary bases are in boldface type. The complementary bases in single-stranded regions are connected by dotted lines. Data are from references 9,
10, 11a, 12, 15, and 21 and this work.
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complementation group. In contrast, P4 seqA405 seqC405 was
able to grow on a P4 lysogen as well as on a strain expressing
P4 immunity from a multicopy plasmid (pGM152); thus, the
double mutant exhibited a virulent phenotype (Table 4).
P4 seqC8 formed turbid plaques and did not seem to be
affected in lysogenization (Table 3); the double mutant P4
seqA8 seqC8 gave clear plaques like those of the single seqA8
mutant and was still sensitive to wild-type P4 immunity (data
not shown).
Effect of a compensatory mutation in seqB on P4 seqA405
seqC405 virulence. The data given above indicate that both
seqA and seqC regions must be mutated in order to make a P4
phage insensitive to the prophage immunity. This suggests that
both seqA and seqC represent functional targets for the P4 CI
immunity factor. If CI RNA-target interactions depend on the
complementarity of seqB with both seqA and seqC, a compen-
satory mutation in seqB that restored the complementarity
between the CI RNA and the mutant target sites should also
restore immunity. To test this prediction, we constructed the
triple mutant P4 seqA405 cI405 seqC405 and assayed its ability
to lysogenize a sensitive host. As can be seen from Table 3 and
4, the cI405 compensatory mutation in the phage was not
sufficient to restore the ability to form turbid plaques and to
lysogenize. However, neither this triple mutant nor the virulent
P4 seqA405 seqC405 double mutant could grow lytically when
a CI RNA carrying the cI405 mutation was expressed from a
multicopy plasmid (pGM85), whereas they were insensitive to
the wild-type immunity expressed by pGM152. Surprisingly,
P41 could not grow with either pGM152 or with pGM85 (Ta-
ble 4) (see Discussion).
Transcription pattern of P4 seqA and seqC mutants. The
effect of the P4 mutations discussed above on transcription
from PLE was then tested by Northern blot analysis. The results
are shown in Fig. 4. Unexpectedly, the kpn1 mutation, which
was introduced into P4 in order to facilitate the in vitro con-
struction of P4 mutant strains, altered the wild-type transcrip-
tion pattern even though it was located upstream of PLE and
did not affect P4 lysogenization efficiency. In P4 kpn1, the
synthesis of the 4.1- and 1.3-kb transcripts was delayed and the
peak of the production of these mRNAs occurred 20 min
postinfection (in the P4 wild type, the peak is at 10 min) (9, 10).
Nevertheless, at 60 min postinfection, the 4.1- and 1.3-kb
FIG. 4. Northern blot analysis of a operon transcription in P4 seqA, seqB,
and seqC mutants. RNA extracted from strain C-1a infected with P4 was frac-
tionated by 1.5% agarose gel electrophoresis and analyzed by Northern blot
hybridization with the riboprobe PLE-t2. The infecting phage mutants and the
times after P4 infection of the RNA extractions (in minutes) are indicated at the
top of the figure (2, noninfected cells). The sizes of the P41 transcripts (10) are
indicated in kilobases at the left. All the phages used carried the additional kpn1
mutation.
TABLE 3. Effect of seqA and seqC mutations on P4 lysogenization
Infecting phagea
Host infected: C-1a(P2 lg) Host infected: C-1a
Survivors
(%)
Yielders
(%)
Burst
sizeb
Lysogens
(%)c
Lysogenization
indexd
Survivors
(%)
P4 plasmid carriers
(%)c
Lysogens
(%)c
Lysogenization
indexd
P4 61 12.5 14 100 4.9 100 1.1 66 60
P4 cI405 0.17 131 53 ,2 ,2.5 3 1025 0.2 4 ,2 ,0.5
P4 seqA8 0.27 93 114 ,2 ,5.8 3 1025 68 3.5e ,1.2 ,0.35
P4 seqA405 0.29 101 68 ,2 ,5.7 3 1025 45 10 ,1.3 ,0.13
P4 seqC8 60 47 75 96 1.2 88 2.1 85 40.5
P4 seqC30 6.1 90 91 85 5.83 1022 72 77f 12g 0.16
P4 seqC405 3.5 108 102 89 2.93 1022 76 90f 8.8g 0.1
P4 seqA405 seqC405 0.36 123 71 ,2 ,5.8 3 1025 1.1 1.1e ,1.1 ,1
P4 seqA405 cI405
seqC405
0.07 107 80 ,2 ,1.3 3 1025 27 98 ,1.1 ,0.01
a All phages but P4 seqC30 carried the additional kpn1 mutation.
b PFUs produced per yielder.
c Among survivors.
d Ratio of lysogens to either plasmid carriers (in C-1a) or yielders (in the P2 lysogen) among infected cells.
e These plasmid carriers were unstable and gave cured clones upon streaking.
f P4 induction by P2 was cox independent; however, these clones were rather unstable and segregated cox-dependent clones upon streaking (see Materials and
Methods).
g P4 induction by P2 was cox dependent; however, these clones were rather unstable and segregated cox-independent clones upon streaking.
TABLE 4. Efficiency of plating and plaque morphology of P4
mutants in the presence of wild-type or
mutant P4 immunity factor
P4 genotypea Efficiency of plating and plaque morphologyb
seqA seqB seqC None (P4) pGM152c pGM85d
1 1 1 1 (t) ,1024 ,1024 ,1024
1 405 1 1 (c) ,1024 ,1024 ,1024
405 1 1 1 (c) ,1024 ,1024 ,1024
1 1 405 1 (c) ,1024 ,1024 ,1024
405 1 405 1 (c) 1 (c) 1 (c) ,1024
405 405 405 1 (c) 1 (c) 1 (c) ,1024
a 1, wild type; 405, mutant.
b Plating was done on C-5201(P2)[2] on the same strain lysogenic for P4 [(P4)]
or carrying the plasmids pGM152 or pGM85. t, turbid; c, clear.
c Expresses the wild-type CI RNA.
d Expresses the CI405 mutant RNA.
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mRNAs disappeared and the 4.5- and 1.7-kb transcripts from
PLL were produced.
For all the seqA and seqC single mutants that were affected
in lysogenization (thus excepting seqC8), the turnoff of the 4.1-
and 1.3-kb RNAs was further delayed relative to that for the P4
kpn1 control. In such mutants, a substantial amount of the 4.1-
and 1.3-kb transcripts was still present 60 min after infection,
and this was larger in seqA than in seqC mutants (Fig. 4). None
of the tested seqA or seqC single mutants produced detectable
amounts of RNA longer than 300 to 400 nt upon infection of
a P4 lysogen (data not shown).
The virulent mutants P4 ash29 seqC30 and P4 seqA405
seqC405 did not turn off expression of the 4.1- and 1.3-kb
transcripts even 60 min postinfection and produced this
mRNA species even in the presence of P4 immunity (Fig. 4 and
data not shown). Interestingly, the triple mutant P4 seqA405
cI405 seqC405, although unable to establish immunity, turned
off the late expression of the 4.1- and 1.3-kb mRNAs. Thus,
restoration of complementarity between seqB and seqA or seqC
suppressed the transcription termination defect observed in
the single and double mutants.
The short transcripts from the immunity region were ana-
lyzed by acrylamide gel electrophoresis, Northern blotting, and
hybridization to riboprobes specific for either the whole im-
munity region (Fig. 5) or the CI RNA (data not shown). P4
seqA mutants produced a higher amount of the 300- to 400-nt
RNAs than did P4 seqC, both in the absence and in the pres-
ence (data not shown) of P4 immunity; however, none of these
mutants was affected in the ability to produce the CI RNA.
DISCUSSION
Identification of seqA and seqC as targets for the P4 CI RNA
immunity factor. Expression of several operons is known to be
controlled by an RNA molecule rather than by a protein. In
most cases analyzed so far, the RNA effector pairs to a com-
plementary region on the transcript to be regulated (cis-acting
element), and this interaction may be directly involved in the
control of transcription elongation, RNA stability or process-
ing, or translation efficiency (for reviews, see references 11, 27,
and 34). Expression of the P4 a operon is controlled by the CI
RNA coded for within the untranslated leader region of the a
operon itself. The CI RNA is the trans-acting factor that pre-
vents transcription of the PLE distal part of the operon, thus
conferring superinfection immunity (10, 11a, 12). In this work,
we have presented evidence that two regions highly comple-
mentary to seqB within the CI RNA, seqA and seqC, are the
targets of the P4 RNA immunity factor and are required in cis
for the negative control of P4 a operon expression.
seqA was identified in a previous work (12) as a region
immediately downstream of PLE that exhibits complementarity
to seqB. Since most recessive immunity-deficient mutations
occurred in seqB and altered the complementarity to seqA, it
was suggested that interactions between CI RNA and the nas-
cent transcript would promote premature transcription termi-
nation of the operon (10, 12). In this work, we show that seqA
is a key element in the P4 lysogenization mechanism since
mutations in seqA (seqA8 and seqA405) that decrease comple-
mentarity with seqB make P4 unable to lysogenize and effi-
ciently shut off transcription of the a operon. However, these
mutations do not allow the mutant phage to escape P4 immu-
nity, thus suggesting that seqA cannot be the only cis-acting site
interacting with the CI RNA.
The presence of a second cis-acting site (seqC) involved in
the immunity control was revealed by the isolation of P4 vir-
ulent mutants that carried either double or triple mutations in
the immunity region. Single mutations in seqC (seqC30 and
seqC405) reduce P4 lysogenization proficiency, whereas muta-
tions in both seqA and seqC (P4 seqA405 seqC405, P4 seqA405
cI405 seqC32, and P4 seqA405 cI405 seqC33) are required for
virulence. The dominant phenotype of the double mutants
suggests that seqA and seqC represent the target sites for the
CI RNA immunity factor. Both functional sites are necessary
to efficiently establish and/or maintain immunity upon infec-
tion, whereas a single site appears to be sufficient to make a
superinfecting phage susceptible to immunity already estab-
lished in the host. The immunity-defective phenotype exhibited
by the seqA and seqC single mutants could be accounted for by
the increased persistence of the 4.1- and 1.3-kb transcripts
from PLE produced upon infection. These transcripts encode a
and other genes necessary for P4 replication and the lytic or
plasmid cycle, and a prolonged expression of such functions
could prevent establishment of lysogeny and/or favor the es-
tablishment of the alternative developmental pathways.
P4 immunity requires interactions between seqB and seqA or
seqC.Most P4 immunity-defective mutants in the cI gene carry
a mutation in seqB that reduces the complementarity to both
seqA and seqC (11a, 12) (Fig. 3). All of the spontaneous mu-
tants we obtained in seqC affect complementarity to seqB, and
three out of four mutants obtained by base-specific substitution
in seqA and/or seqC have altered immunity. These observations
indicate that complementarity between seqB and seqA or seqC
is relevant for P4 immunity.
The most obvious target for an RNA effector is a comple-
mentary RNA molecule. Evidence that CI RNA may interact
with another RNA molecule by pairing to the complementary
sequence seqA can be found in the analysis of the anti-immu-
nity effect. Transcription of seqA is required for anti-immunity,
and anti-immunity may be abolished by a mutation in seqA,
decreasing complementarity with seqB.
On the basis of these data, we suggest a basic model for P4
immunity. (i) The CI RNA is the trans-acting immunity factor.
(ii) The CI RNA interacts with the RNA transcribed from PLE
by base pairing of seqB with the complementary regions seqA
and seqC (Fig. 3B); intramolecular pairing of seqB with either
seqA or seqC might occur as well. (iii) As a consequence,
transcription from PLE terminates prematurely and expression
of P4 replication genes is prevented.
FIG. 5. Northern blot analysis of the transcripts from the immunity region of
P4 seqA and seqC mutants. The RNA was fractionated by 10% acrylamide–7 M
urea gel electrophoresis, electroblotted, and hybridized to probe PLE-t2. The
sizes of the transcripts are indicated in kilobases at the left. The times after
infection of the extractions (in minutes) are indicated at the top of the figure (2,
noninfected cells). All the phage used carried the additional kpn1 mutation.
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A role for seqC in the transcription termination mechanism
is suggested by the observation that the distal part of seqC,
seqC0, overlaps the ribosome-binding site and the start codon
of kil, the first translated gene downstream of PLE (11a, 12)
(Fig. 3). The pairing of seqB with seqC might prevent transla-
tion of kil and cause premature transcription termination by a
polar effect.
Mutations in seqA have a more drastic effect on P4 immunity
and transcription termination of the a operon than do muta-
tions in seqC, since no P4 lysogens could be isolated and the
long transcripts from PLE were abundantly expressed up to 1 h
after P4 seqA infection. It might be suggested that seqA-seqB
pairing may promote transcription termination, for example,
by allowing the formation of alternative RNA secondary struc-
tures that favor RNA polymerase pausing and release and/or
the recruitment of host transcription termination factors.
Virulent mutants of P4. Transcription from the late pro-
moter PLL is insensitive to the termination mechanism con-
trolled by P4 immunity (10). Thus, vir1-like mutants, which
carry mutations that make PLL independent of its positive
regulator (9, 20, 23a), do not provide information on the tar-
gets of the trans-acting immunity factor.
The second class of P4 virulent mutants we have isolated
carry a mutation both in seqA and in seqC. This strongly sug-
gests that seqA and seqC are the cis-acting elements required
for P4 immunity sensitivity. The need for a double mutation to
create this type of virulent mutant explains why the virulent
mutants obtained in vivo most frequently carried a PLL pro-
moter up mutation.
A third class of virulent mutants is represented by P4 ash29
seqC30. The single seqC30 mutation does not confer a virulent
phenotype, so it appears that the peculiar combination of
ash29 and seqC30 is required for P4 immunity insensitivity. An
analysis of this virulent mutant might help an understanding of
the molecular details of the P4 immunity process.
A compensatory mutation in seqB that restored complemen-
tarity with the mutant seqA and seqC (see the triple mutant P4
seqA405 cI405 seqC405) also restored premature transcription
termination, therefore preventing late transcription of the
whole a operon from PLE. However, the compensatory muta-
tion could not reestablish lysogenization proficiency. It may be
suggested that small differences in the timing and/or efficiency
of premature transcription termination may be relevant for the
choice of the lysogenic condition. This could be influenced by
the stringency of the seqB interaction with seqA or seqC. It
should be noted that in these mutants, a UA pairing substitutes
for the wild-type CG interaction (Fig. 3). It is possible that this
weaker interaction is sufficient to substantially terminate tran-
scription upon infection when a large amount of CI RNA is
produced but may be too leaky to fully prevent a operon
expression and maintain immunity. High levels of CI RNAmay
compensate for a weaker seqB interaction with seqA or seqC. In
fact, P4 seqA405 seqC405 and P4 seqA405 cI405 seqC405 mu-
tants do not grow in the presence of CI405 RNA (UA pairing)
expressed by a multicopy plasmid but do form plaques with
CI1 RNA (CA mismatch); on the other hand, a P4 wild type
cannot grow with either a wild-type CI (CG pairing) or CI405
(UG pairing) RNA. However, when the plasmid expressing the
CI405 RNA is carried in a low copy number, both P41 and the
double and triple seq mutants can grow (data not shown).
P4 immunity establishment versus maintenance. Both seqA
and seqC single mutants are sensitive to the P4 CI immunity
factor since (i) they do not grow on a P4 lysogen (in such a
host, transcription of these phage mutants from PLE is effi-
ciently terminated) and (ii) in cross-streak complementation
tests with either P41 or P4 cII, they form a turbid spot. On the
other hand, both types of mutants produce a wild-type CI
RNA. It is therefore somewhat paradoxical that these mutants
form clear plaques, do not lysogenize (seqA mutants) or lyso-
genize at a reduced frequency (seqC mutants), and are unable
to complement cI mutants. It should be considered, however,
whether a delay of a reduced efficiency of the a operon tran-
scription termination upon infection might allow the irrevers-
ible onset of the alternative lytic or plasmid pathway. Further-
more, the establishment of lysogeny may demand different (or
more stringent) requirements than its maintenance. This idea
is supported by other situations that greatly reduce lysogeni-
zation frequency without being incompatible with immunity
maintenance, such as the anti-immunity effect due to the ex-
pression of the cloned seqA region or mutations in the tran-
scription termination factor Rho of the host (8a).
Relationship to other systems. The retronphage fR73 is
related to P4, and the two phages share a high degree of
homology (18, 31). The putative fR73 cI gene sequence pre-
sents six base changes, all in seqB. It is noteworthy that for five
of these changes, there is a complementary base substitution in
both seqA and seqC, and the sixth is a C3U transition, still
compatible for pairing with the G in the target sequences.
fR73 is heteroimmune to P4 (27a). This supports the idea that
the pairing of seqB to seqA or seqC is important for immunity
and that immunity specificity is provided by seqA, seqB, and
seqC sequences.
The control of P4 a operon expression exhibits striking sim-
ilarities to the regulation of the phage P1 immI operon that
codes for the P1 antirepressor (6, 24; for a review, see refer-
ence 16). The immI untranslated leader region is processed to
produce a 77-nt RNA (C4 RNA), the trans-acting factor that
negatively regulates the operon (5, 6). The C4 RNA bears
extended complementarity with the translation initiation sig-
nals of icd, the first gene of the operon (5, 24). RNA-RNA
interactions between these complementary sequences prevent
translation of icd, thus preventing expression of the down-
stream antirepressor gene by causing Rho-dependent tran-
scription termination (3).
The predicted secondary structures of P4 CI and P1 C4
RNAs and of the leader transcripts of the two operons are
remarkably similar, and a limited sequence homology can also
be detected (21). Thus, the two regulatory systems appear to be
evolutionarily related.
P1 C4 RNA exhibits complementarity to both the upstream
and the downstream sequences in the leader transcript. It
seems, however, that the upstream sequence plays a different
role in the two phages. In fact, in P1, only the downstream
sequence is involved in the negative regulation of the operon,
whereas the upstream sequence appears to antagonize this
regulatory mechanism (5). In P4, both the upstream and the
downstream sequences promote transcription termination. In
P1, c4 indirectly enables the establishment and maintenance of
lysogeny by controlling the expression of an anti-immunity
factor, whereas in P4, the cI gene encodes the immunity factor
itself. It is conceivable that the different physiological roles of
the two regulatory systems caused two homologous molecular
structures to evolve different functions.
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